In December 1999, one year after the merger of Hoechst and Rhône-Poulenc, the new company Aventis had increased its revenues, operating margins and reduced costs. It was also well-positioned to achieve some of its major strategic goals. In November 2000, Aventis announced its decision to sell of its crop sciences operations. In this way, Aventis became a focussed pharmaceuticals company.
Keywords
Mergers and Acquisitions, Pharmaceuticals, Integration
Settings
World/global
December 1999
Available Languages
English
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.
Copyright Information
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
